WO1998058956A3 - Procedes ameliores visant a induire une reponse immunitaire - Google Patents

Procedes ameliores visant a induire une reponse immunitaire Download PDF

Info

Publication number
WO1998058956A3
WO1998058956A3 PCT/US1998/012894 US9812894W WO9858956A3 WO 1998058956 A3 WO1998058956 A3 WO 1998058956A3 US 9812894 W US9812894 W US 9812894W WO 9858956 A3 WO9858956 A3 WO 9858956A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
immune response
inducing
response involving
boost protocols
Prior art date
Application number
PCT/US1998/012894
Other languages
English (en)
Other versions
WO1998058956A2 (fr
Inventor
Guy Warnier
Catherine Uyttenhove
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Priority to AU79831/98A priority Critical patent/AU7983198A/en
Publication of WO1998058956A2 publication Critical patent/WO1998058956A2/fr
Publication of WO1998058956A3 publication Critical patent/WO1998058956A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés améliorés destinés à moduler une réponse immunitaire contre un antigène, au moyen d'adénovirus exprimant cet antigène et permettant d'amorcer l'immunisation, et de peptides antigéniques favorisant cette immunisation. Ces peptides sont de préférences combinés à un adjuvant QS21/MPL. L'invention concerne plus particulièrement des procédés d'immunisation contre des antigènes tumoraux, ainsi que des kits d'immunisation.
PCT/US1998/012894 1997-06-23 1998-06-19 Procedes ameliores visant a induire une reponse immunitaire WO1998058956A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU79831/98A AU7983198A (en) 1997-06-23 1998-06-19 Improved methods for inducing an immune response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88097997A 1997-06-23 1997-06-23
US08/880,979 1997-06-23

Publications (2)

Publication Number Publication Date
WO1998058956A2 WO1998058956A2 (fr) 1998-12-30
WO1998058956A3 true WO1998058956A3 (fr) 1999-03-18

Family

ID=25377532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/012894 WO1998058956A2 (fr) 1997-06-23 1998-06-19 Procedes ameliores visant a induire une reponse immunitaire

Country Status (3)

Country Link
AU (1) AU7983198A (fr)
WO (1) WO1998058956A2 (fr)
ZA (1) ZA985460B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
WO2001030847A1 (fr) 1999-10-22 2001-05-03 Aventis Pasteur Limited Molecule gp100 modifiee et ses applications
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US8921534B2 (en) 2001-12-12 2014-12-30 Sanofi Pasteur Limited Enhancement of the immune response using CD36-binding domain
PL1635863T3 (pl) * 2003-06-17 2011-01-31 Mannkind Corp Kompozycje do wywoływania, wzmacniania i utrzymywania odpowiedzi immunologicznych na epitopy ograniczone do MHC klasy I do celów profilaktycznych i leczniczych
JP2008503494A (ja) * 2004-06-17 2008-02-07 マンカインド コーポレイション 診断方法を治療方法と統合することによる免疫療法の効力改善
CN101146550B (zh) * 2004-12-29 2013-04-17 曼康公司 免疫原性组合物用于制备引发和增强免疫应答的试剂盒的用途
WO2006113540A2 (fr) 2005-04-14 2006-10-26 Duke University Utilisation d'un agent qui restaure l'irrigation et l'oxygenation des tissus
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
BRPI0716959A2 (pt) * 2006-09-26 2013-10-29 Infectious Disease Res Inst Composição de vacina contendo adjuvante sintético
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
CA2743669C (fr) 2008-11-24 2018-10-16 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Recepteur de lymphocytes t de forte affinite et ses applications
EP3124491B1 (fr) 2009-06-05 2019-10-30 Infectious Disease Research Institute Adjuvants lipidiques synthétiques à base de glucopyranosyle et compositions de vaccin ainsi que compositions pharmaceutiques les contenant
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
WO2014031178A1 (fr) 2012-08-24 2014-02-27 Etubics Corporation Vecteur adénoviral à réplication déficiente, utile en vaccination
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
HRP20220872T1 (hr) 2015-10-22 2022-12-23 Modernatx, Inc. Cjepiva protiv respiratornih virusa
EP3551193A4 (fr) 2016-12-08 2020-08-19 Modernatx, Inc. Vaccins à acide nucléique contre des virus respiratoires
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANCHINI ET AL: "Highly Attenuated HIV Type 2 Recombinant Poxviruses, but Not HIV-2 Recombinant Salmonella Vaccines, Induce Long-Lasting Protection in Rhesus Macaques", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 11, 1995, pages 909 - 920, XP002079473 *
PIALOUX ET AL: "A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 11, 1995, pages 373 - 381, XP002079474 *
WARNIER G ET AL: "Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A.", INTERNATIONAL JOURNAL OF CANCER, (1996 JUL 17) 67 (2) 303-10. JOURNAL CODE: GQU. ISSN: 0020-7136., UNITED STATES, XP002079472 *
ZHAI Y ET AL: "Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.", JOURNAL OF IMMUNOTHERAPY, (1997 JAN) 20 (1) 15-25. JOURNAL CODE: CUQ., UNITED STATES, XP002036182 *

Also Published As

Publication number Publication date
ZA985460B (en) 1999-01-26
AU7983198A (en) 1999-01-04
WO1998058956A2 (fr) 1998-12-30

Similar Documents

Publication Publication Date Title
WO1998058956A3 (fr) Procedes ameliores visant a induire une reponse immunitaire
EP1335023A3 (fr) Méthodes et réactifs pour induire une vaccination basée sur la production de cellules T CD8+
WO1998037095A3 (fr) Poxvirus recombine destine a une immunisation contre l'antigene associe aux tumeurs muc1
WO2000067761A8 (fr) Compositions et procedes d'identification d'antigenes provoquant une reponse immunitaire
WO1995029193A3 (fr) Antigenes du melanome
WO2001034801A3 (fr) Vaccins contenant de la gelatine recombinante
WO2000029428A3 (fr) Polypeptide
WO2000073430A3 (fr) Vaccins contre des antigenes dependant de la conformation ainsi que contre des antigenes qui ne sont pas ou pas exclusivement des proteines ou des peptides
WO2001082963A3 (fr) Synchronisation d'epitopes dans des cellules presentant des antigenes
CA2259140A1 (fr) Procede d'activation de cellules dendritiques
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
EP2311952A3 (fr) Anticorps dirigé vers MART-1 protéine et ses fragments
WO1989001973A3 (fr) Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
WO2002034205A3 (fr) Utilisation des proteines du stress pour stimuler la reponse immunitaire
WO2000054802A3 (fr) Technique
IL126803A0 (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
WO2003011331A3 (fr) Matieres et techniques relatives a des strategies de vaccination ameliorees
WO1996021734A3 (fr) Antigenes p15 et tyrosinase du melanome et leur utilisation dans des procedes diagnostiques et therapeutiques
WO2000012122A3 (fr) Fragments de l'acide hyaluronique de faible poids moleculaire pour la preparation de vaccins
WO1999002132A3 (fr) Utilisation d'emulsions huile dans eau submicroniques avec des vaccins a adn
NZ213303A (en) Plasmodium protein, dna sequence and vaccine
CO5280140A1 (es) Antigeno (c42) asociado a tumores
WO2000047227A3 (fr) IMMUNISATION CONTRE $i(MYCOBACTERIUM TUBERCULOSIS)
WO2000063242A8 (fr) Acides nucleiques et polypeptides de lyssavirus chimeres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999504909

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA